Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval

Bladder cancer is a prevalent malignancy with limited therapeutic options, particularly for patients who are unresponsive to Bacillus Calmette-Guérin (BCG). The approval of interferon-α (IFNα) gene therapy with nadofaragene firadenovec (Adstiladrin®), the first gene therapy for genitourinary malignancies, has provided a promising alternative. This article reviews the research and milestones that led to the development and approval of nadofaragene firadenovec. Bladder cancer is well-suited for gene therapy due to direct access to the bladder and the availability of urine and tissue samples for monitoring. Early challenges included effective gene transfer across the urothelium, which was overcome initially by modulating the expression of coxsackie/adenovirus receptor (CAR) and, ultimately, by disrupting the urothelial barrier with Syn3. Nadofaragene firadenovec is a modified adenoviral vector carrying the IFNα gene. Clinical trials have shown promising results, with high response rates and manageable adverse events. Ongoing research focuses on improving patient selection, identifying biomarkers for response prediction, exploring alternative vectors for enhanced transfection efficiency, and developing combination strategies targeting resistance mechanisms. The approval of nadofaragene firadenovec marks a significant milestone in the field of gene therapy for bladder cancer, and future developments hold promise for further enhancing its efficacy and impact.

[1]  A. Patel,et al.  Physical activity, obesity, and bladder cancer incidence , 2023, Cancer Causes & Control.

[2]  C. Dinney,et al.  The current status of gene therapy in bladder cancer , 2023, Expert review of anticancer therapy.

[3]  Sam S. Chang,et al.  Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer , 2022, Current Oncology Reports.

[4]  Anirban P. Mitra,et al.  Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial , 2021, European Urology.

[5]  G. Andriole,et al.  Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. , 2020, The Lancet. Oncology.

[6]  L. Egevad,et al.  The natural history of untreated muscle‐invasive bladder cancer , 2020, BJU international.

[7]  C. Dinney,et al.  The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside , 2018, World Journal of Urology.

[8]  Anirban P. Mitra,et al.  Lentiviral interferon: A novel method for gene therapy in bladder cancer , 2018, Molecular therapy oncolytics.

[9]  K. Ogan,et al.  Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  H. Grossman,et al.  Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon α2b Formulated in Syn3 for Failures of Bacillus Calmette–Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer , 2016, Annals of Surgical Oncology.

[11]  C. Dinney,et al.  Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG , 2015, Bladder cancer.

[12]  C. Dinney,et al.  Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer. , 2013, The Journal of urology.

[13]  C. Dinney,et al.  Direct cytotoxicity produced by adenoviral-mediated interferon α gene transfer in interferon-resistant cancer cells involves ER stress and caspase 4 activation , 2011, Cancer Gene Therapy.

[14]  R. Connor,et al.  Enhancement of intravesical delivery with Syn3 potentiates interferon-alpha2b gene therapy for superficial bladder cancer. , 2007, Cytokine & growth factor reviews.

[15]  C. Dinney,et al.  Interferon-α Induces TRAIL Expression and Cell Death Via an IRF-1-Dependent Mechanism in Human Bladder Cancer Cells , 2007 .

[16]  B. Bochner,et al.  Adenoviral Receptor Expression of Normal Bladder and Transitional Cell Carcinoma of the Bladder , 2007, Urologia Internationalis.

[17]  A. Sabichi,et al.  Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression. , 2006, The Journal of urology.

[18]  C. Dinney,et al.  Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation , 2006, Cancer Gene Therapy.

[19]  C. Dinney,et al.  Intravesical Ad-IFNα Causes Marked Regression of Human Bladder Cancer Growing Orthotopically in Nude Mice and Overcomes Resistance to IFN-α Protein , 2004 .

[20]  M. Lamfers,et al.  Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells , 2004, Cancer Gene Therapy.

[21]  B. Wiedenmann,et al.  Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. , 2003, Journal of the National Cancer Institute.

[22]  B. Czerniak,et al.  Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer , 2002, Cancer Gene Therapy.

[23]  G. Demers,et al.  Interferon α2b gene delivery using adenoviral vector causes inhibition of tumor growth in xenograft models from a variety of cancers , 2001, Cancer Gene Therapy.

[24]  C. Dinney,et al.  Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  A. Sagalowsky,et al.  Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. , 1999, Cancer research.

[26]  J. Nickel,et al.  Relative efficacy of various exogenous glycosaminoglycans in providing a bladder surface permeability barrier. , 1998, The Journal of urology.

[27]  C. Bucana,et al.  Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. , 1998, Cancer research.

[28]  R. Burnham,et al.  Multidisciplinary chronic pain management in a rural Canadian setting. , 2010, Canadian journal of rural medicine : the official journal of the Society of Rural Physicians of Canada = Journal canadien de la medecine rurale : le journal officiel de la Societe de medecine rurale du Canada.

[29]  L. Trümper From bench to bedside , 2005, Medizinische Klinik.

[30]  C. Dinney,et al.  Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[31]  H. Engler,et al.  Identification of polyamides that enhance adenovirus-mediated gene expression in the urothelium , 2001, Gene Therapy.